Get started
Author

Javier Gavira

Circulating leukocyte–platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents
2021 · Carlos Zamora, Mariona Riudavets, et al. · Cancer Immunology Immunotherapy · 19
Immunotherapy-induced isolated ACTH deficiency in cancer therapy
2021 · Pedro Iglesias, Inmaculada Peiró, et al. · Endocrine Related Cancer · 17
What About Variant Histologies in Bladder Cancer?
2024 · Elizabeth Day, Javier Gavira, et al. · European Urology Focus · 10
Blood-based circulating biomarkers for prediction of immune-checkpoint inhibitors efficacy in renal cell carcinoma
2024 · Loubna Omri, Marie Naigeon, et al. · Exploration of Targeted Anti-tumor Therapy · 7
PDF
Activity of lenvatinib-based therapy in previously treated patients with metastatic renal cell carcinoma: A European multicenter study (LENVA-LAT)
2025 · Javier Gavira, Edouard Auclin, et al. · European Journal of Cancer · 6
Capecitabine-Related Thrombotic Microangiopathy
2024 · Francisco J. Pelegrín Mateo, Anna Dominguez Guasch, et al. · Journal of Gastrointestinal Cancer · 5
Treatment Patterns and Survival Outcomes Before and After Access to Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma: A Single-Center Retrospective Study From 2004 to 2021
2024 · Jose C. Tapia, Freya Bosma, et al. · Clinical Genitourinary Cancer · 3
Ninety‐day mortality and clinical outcomes of patients with solid tumours and COVID ‐19 infection during the first pandemic outbreak in Catalonia, Spain: A multicentre retrospective study
2021 · Jose Carlos Tapia, Javier Gavira, et al. · International Journal of Cancer · 2
1719P Clinical characteristics and 28-day mortality among patients with solid cancers and COVID-19 in a tertiary hospital
2020 · J.C. Tapia, J. Gavira, et al. · Annals of Oncology · 2
PDF
P-278 Survival impact and predictive scores for thrombosis associated with pancreatic ductal adenocarcinoma (PDAC)
2023 · A. Romano, J. Gavira, et al. · Annals of Oncology · 1
PDF
The FLARE score, circulating neutrophils, and association with COVID-19 outcomes in patients with solid tumors.
2022 · Elia Seguí, Edouard Auclin, et al. · Journal of Clinical Oncology · 1
30 Myeloid- Versus Effector-Driven Circulating Immune States Define Treatment-Specific Benefit in Metastatic Clear Cell Renal Cell Carcinoma
2026 · Mariangela Calabrese, Nathalie Chaput, et al. · The Oncologist
PDF
58 Baseline Peripheral TCR Diversity as a Biomarker of Response to First-line Immunotherapy in Metastatic Clear Cell Renal Cell Carcinoma
2026 · Luigi Roca, Nathalie Chaput, et al. · The Oncologist
PDF
First-line tivozanib in favorable- and very favorable–risk metastatic renal cell carcinoma: Real-world evidence from the TIVOREAL-SOGUG study.
2026 · Cristina Pernaut Sanchez, Laura López, et al. · Journal of Clinical Oncology
Circulating angiogenic–myeloid cytokine axis to predict benefit from first-line immune-checkpoint inhibitor combinations in metastatic clear cell renal cell carcinoma.
2026 · Mariangela Calabrese, Nathalie Chaput, et al. · Journal of Clinical Oncology
PDF
International analysis of reimbursement rates and clinical benefit of genitourinary cancer drugs across Canada, France, England, Wales, Scotland, Spain, Italy, and Portugal
2026 · Jose C. Tapia, Javier Gavira, et al. · International Journal of Cancer
Lenvatinib's efficacy in heavily pre-treated metastatic renal cell carcinoma: Insights from a European multicenter study.
2025 · Javier Gavira, Edouard Auclin, et al. · Journal of Clinical Oncology
Disparities in Clinical and Coverage Benefit of Drugs for Genitourinary Cancers: Cross-National Analysis in the USA, Canada, France, United Kingdom, Spain, Italy and Portugal
2025 · Jose C. Tapia, Javier Gavira, et al. · SSRN Electronic Journal
P172 Analysis of circulating tumor DNA in treatment-naive patients with metastatic renal cell carcinoma
2024 · M. Rey Cárdenas, J. Gavira, et al. · European Urology Open Science
2019P Disparities in urothelial carcinoma (UC) drug approval: Contrasting North America and Europe
2024 · J.C. Tapia, J. Gavira, et al. · Annals of Oncology
1556P Current landscape of drug approvals for genitourinary (GU) cancers in North America and Europe
2024 · J.C. Tapia, J. Gavira, et al. · Annals of Oncology
CN79 Quality-of-Life (QoL) data published by clinical trials supporting drug approvals for renal cell carcinoma (RCC)
2024 · R.E. Seadon, J.C. Tapia, et al. · Annals of Oncology
PDF
The FLARE Score and Circulating Neutrophils in Patients with Cancer and COVID-19 Disease
2024 · Elia Seguí, Juan Torres Canizales, et al. · Cancers
PDF
Challenges of diagnosing homologous recombination deficiencies in metastatic prostate cancer: a six-year experience from a single institution
2024 · Javier Gavira, Jose Carlos Tapia, et al. · Clinical & Translational Oncology
Cumulative incidences of hypogonadism, hypertension, and dyslipidaemia in patients with stage I seminoma treated with a risk-adapted strategy: a Spanish single-centre retrospective analysis
2024 · Jose C. Tapia, Javier Gavira, et al. · Clinical & Translational Oncology
Works count: 35
Citation count: 73
H-index: 5
I10-index: 3
Year
Topic
Type